The aim of the present investigation was to increase the gastric residence time of cefuroxime axetil by preparing gastro retentive mucoadhesive tablet, thereby improving bioavailability of cefuroxime axetil. Tablets were prepared using different mucoadhesive polymers such as hydroxypropylmethyl cellulose K4M, carbopol 974P, sodium alginate, and chitosan in combination ratios by wet granulation method. All the batches were subjected to various evaluation parameters such as physicochemical properties, swelling index, in vitro residence time, and in vitro drug release. Optimized formulation containing carbopol 974P and chitosan in combination (F6) exhibited maximum in vitro residence time of 10.05 h and in vitro release up to 45.89% in 10 h. The F6 formulation was further subjected to in vitro permeation, scanning electron microscope (SEM), stability studies and in vivo residence time. SEM revealed smooth surface characteristics with increasing pore diameter, indicating the diffusion mechanism of release. Stability was conducted as per International Conference on Harmonisation (ICH) guidelines at 40 ± 20°C/75 ± 5% relative humidity (RH) and the values were within permissible limits. In vivo X-ray photographs taken during the experiment showed mucoadhesion to the gastric mucosa up to 10 h.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.